Holitilin, 400 mg capsules 28 pcs

Pharmacodynamics

Choline alphoscerate, is a cholinomimetic of central action with predominant effect on the central nervous system.

The preparation contains 40.5% choline which is released from the compound in the brain; choline is involved in the biosynthesis of acetylcholine (one of the main mediators of nerve excitation). Alphoscerate is biotransformed to glycerophosphate, which is a precursor of phospholipids.

Acetylcholine has a positive effect on nerve impulse transmission, and glycerophosphate participates in the synthesis of phosphatidylcholine (membrane phospholipid), as a result improving membrane elasticity and receptor function.

Choline alphoscerate increases metabolic processes and activates structures of the reticular formation of the brain.

It has preventive and corrective effects on factors of involutional psycho-organic syndrome, such as changes in the phospholipid composition of neuronal membranes and decreased cholinergic activity.

Pharmacodynamic studies have shown that choline alphoscerate acts on synaptic, including cholinergic transmission of nerve impulse (neurotransmission), neuronal membrane plasticity and receptor function.

Pharmacokinetics

Absorption when ingested is 88%; easily penetrates the blood-brain barrier, accumulates primarily in the brain (concentration in the brain reaches 45% of blood levels), lungs and liver; 85% is excreted by the lungs as carbon dioxide, the remaining amount (15%) is excreted by the kidneys and through the intestines.

It does not affect the reproductive cycle, has no teratogenic and mutagenic effects.

Indications

Mental disorders, Attention and memory disorders, Stroke aftermath, Impaired cerebral circulation, Acquired dementia, Aggressiveness and conflict, Headache, Alzheimer’s disease

• Cerebral circulation disorders of the ischemic type (acute and recovery periods) and hemorrhagic type (recovery period).

• Psychoorganic syndrome against involutionary and degenerative processes of the brain.

• Consequences of cerebrovascular failure or primary and secondary cognitive impairment in the elderly, characterized by memory impairment, confusion, disorientation, decreased motivation and initiative, decreased concentration.

• Behavioral and affective disorders in old age: emotional lability, increased irritability, decreased interest; senile pseudo-melancholy.

• Multi-infarct dementia.

.

Active ingredient

Choline alphoscerate

Composition

One capsule contains:

The active ingredient:

• choline alphoscerate hydrate, in terms of choline alphoscerate 400.00 mg;

excipients:

• purified water 109.00 mg,

• povidone K-15 1.00 mg, macrogol (polyethylene glycol 400) to give the contents of the capsule mass of 640.00 mg;

soft gelatin capsule 250.000 mg, including: purified water* 151.64 mg, glycerol (glycerin) 41.090 mg, gelatin 164.313 mg, iron oxide yellow dye 0.770 mg, iron oxide red dye 0.154 mg, iron oxide black dye 0.169 mg, methyl parahydroxybenzoate 1.166 mg, propyl parahydroxybenzoate 0.164 mg, sorbitol 41.500 mg, titanium dioxide 0.674 mg.

* – not present in the finished product.

How to take, the dosage

Capsules are taken orally before meals with water.

1 capsule (400 mg) 2-3 times a day. The doctor determines the duration of treatment individually, depending on the clinical picture and characteristics of the course of the disease, age and tolerance of the drug.

Special Instructions

When treating, caution should be exercised when driving motor vehicles and engaging in other potentially dangerous activities that require increased concentration and quick psychomotor reactions.

.

Contraindications

Hypersensitivity, hemorrhagic stroke (acute stage), pregnancy, lactation, children under 18 years of age.

.

Side effects

Digestive system disorders: gastritis, peptic ulcer, pharyngitis.

Nervous system disorders: nervousness, cerebral ischemia, seizures, hyperkinesia, dizziness.

Others: allergic reactions, increased frequency of urination.

Interaction with other medicinal products

Drug interactions of the drug have not been established.

.

Overdose

• Symptoms: nausea.
• Possible increase in the severity of dose-dependent side effects.
• Treatment: symptomatic therapy.
• Dialysis efficacy has not been established.

Pregnancy use

The use of the drug Holitilin during pregnancy and during breast-feeding is contraindicated.

Similarities

Gliatilin, Cerepro, Cereton, Holitilin, Noocholin Rompharma, Choline alphoscerate